Quinonez, Camila G., Lee, Jae Jin, Lim, Juhyeon, Odell, Mark, Lawson, Christopher P., Anyogu, Amarachukwu ORCID: https://orcid.org/0000-0001-9652-7728, Raheem, Saki and Eoh, Hyungjin (2022) Fatty acid metabolism of Mycobacterium tuberculosis: a double-edged sword. Microbial Cell, 9 (5). pp. 123-125.

Preview	PDF 2022A-Quinonez-Microbial-Cell.pdf - Published Version Available under License Creative Commons Attribution. Download (431kB) | Preview
Preview	PDF 7. Fatty acid_Review.pdf - Accepted Version Available under License Creative Commons Attribution. Download (441kB) | Preview

Abstract

Unlike other heterotrophic bacteria, Mycobacterium tuberculosis (Mtb) can co-catabolize a range of carbon sources simultaneously. Evolution of Mtb within host nutrient environment allows Mtb to consume the host’s fatty acids as a main carbon source during infec- tion. The fatty acid-induced metabolic advantage greatly contributes to Mtb’s pathogenicity and viru- lence. Thus, the identification of key enzymes involved in Mtb’s fatty acid metabolism is urgently needed to aid new drug development. Two fatty acid metabolism enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and isocitrate lyase (ICL) have been intensively studied as promising drug targets, but recently, Quinonez et al. (mBio, doi: 10.1128/mbio.03559-21) highlighted a link between the fatty acid-induced dormancy-like state and drug tolerance. Using metabolomics profiling of a PEPCK-deficient mutant, Quinonez et al. identified that over-accumulation of methylcitrate cycle (MCC) inter- mediates are phenotypically associated with enhanced drug tolerance against first- and second- line TB antibi- otics. This finding was further corroborated by metabolomics and phenotypic characterization of Mtb mutants lacking either ICL or 2-methylcitrate dehydra- tase. Fatty acid metabolism induced drug-tolerance was also recapitulated in wildtype Mtb after treatment with authentic 2-methylisocitrate, an MCC intermedi- ate. Together, the fatty acid-induced dormancy-like state and drug tolerance are attributed to dysregulat- ed MCC activity.

Item Type:	Article
Identifier:	10.15698/mic2022.05.777
Additional Information:	© 2022 Quinonez et al. This work was supported by start-up funding from the Department of Molecular Microbiology and Immunology (Keck School of Medicine, USC), American Lung Association (Innovation Award), and NIH (AI139386 and AI143870) to H.E., and the Quintin Hogg Foundation, the Company of Biologists, Biochemical Society, and the University of Westminster to S.R.
Keywords:	tuberculosis, metabolomics, drug tolerance, fatty acids, methylcitrate cycle
Subjects:	Medicine and health > Microbiology Medicine and health
Related URLs:	Publisher Publisher
Depositing User:	Amarachukwu Anyogu
Date Deposited:	28 Feb 2022 19:04
Last Modified:	04 Nov 2024 11:23
URI:	https://repository.uwl.ac.uk/id/eprint/8811

Downloads

Actions (login required)

View Item